Study of SC0062 for IgA Nephropathy with Proteinuria
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests an experimental drug (SC0062 capsule) for people with IgA nephropathy who have protein in their urine. It aims to see if the drug can help reduce kidney damage when added to standard treatments like blood pressure medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and have a confirmed diagnosis of IgA nephropathy from a kidney biopsy.
- You need to have high protein in your urine (at least 0.75 grams per gram of creatinine or 1.0 grams per day) based on two tests done after being on a stable dose of certain blood pressure or kidney medications for at least 12 weeks.
- Your kidney function (eGFR) must be between 30 and 90 mL/min/1.73m², and you must be on a stable dose of medications like ACE inhibitors, ARBs, SGLT2 inhibitors, or others for at least 12 weeks.
- You cannot have other kidney diseases, recent use of strong immune-suppressing drugs, severe heart or liver problems, or certain other health conditions.
- If you are able to have children, you must use effective birth control during the study and for 3 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication for IgA nephropathy, a kidney disease that causes inflammation and protein loss in urine. It aims to see if the drug can safely slow down kidney damage and protect kidney function.
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
This study tests a new drug, MY008211A, for people with a type of kidney disease called IgA nephropathy. The goal is to see if it can reduce protein in the urine and help protect kidney function. You must have had a kidney biopsy confirming the diagnosis and be on stable standard care.
This study continues treatment with an experimental medicine called HSK39297 for people with IgA nephropathy, a condition where the immune system damages the kidneys. The trial will track how safe and effective the medicine is over time in people who already completed an earlier study.
This trial tests a new drug, SHR-2173, for people with IgA nephropathy who still have a lot of protein in their urine despite standard care. The goal is to see if it can help protect kidney function.
This trial tests whether a daily supplement of short-chain fatty acids (SCFAs) can slow down kidney damage in people with IgA nephropathy. SCFAs are substances made by gut bacteria that may help reduce inflammation and protect the kidneys.
Hear when a new IgA Nephropathy (IgAN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.